CO MYCOPHENOLATE TABLET
Země: Kanada
Jazyk: angličtina
Zdroj: Health Canada
Charakteristika produktu
(SPC)
22-10-2013
Některé dokumenty pro tento produkt momentálně nejsou k dispozici, můžete poslat požadavek našemu zákaznickému servisu a my vás upozorníme, jakmile je dokážeme získat.
Poslat žádost.
Poslat žádost.
Aktivní složka:
MYCOPHENOLATE MOFETIL
Dostupné s:
COBALT PHARMACEUTICALS COMPANY
ATC kód:
L04AA06
INN (Mezinárodní Name):
MYCOPHENOLIC ACID
Dávkování:
500MG
Léková forma:
TABLET
Složení:
MYCOPHENOLATE MOFETIL 500MG
Podání:
ORAL
Jednotky v balení:
50/100
Druh předpisu:
Prescription
Terapeutické oblasti:
IMMUNOSUPPRESSIVE AGENTS
Přehled produktů:
Active ingredient group (AIG) number: 0128158002; AHFS:
Stav Autorizace:
CANCELLED POST MARKET
Datum autorizace:
2018-05-07
Charakteristika produktu
_ _
_ _
_Page 1 of 55_
PRODUCT MONOGRAPH
PR
_CO_ MYCOPHENOLATE
Mycophenolate Mofetil Tablets USP
500 mg
Immunosuppressive Agent
Cobalt Pharmaceuticals Company
6500 Kitimat Road
Mississauga, Ontario
L5N 2B8
SUBMISSION CONTROL NO: 168316
Date of Revision:
October 16, 2013
_ _
_ _
_Page 2 of 55_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
7
DRUG INTERACTIONS
.................................................................................................
15
DOSAGE AND ADMINISTRATION
.............................................................................
18
OVERDOSAGE
...............................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 20
STORAGE AND STABILITY
.........................................................................................
27
SPECIAL HANDLING INSTRUCTIONS
......................................................................
27
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 27
PART II: SCIENTIFIC INFORMATION
..............................................................................
28
PHARMACEUTICAL INFORMATION
.........................................................................
28
CLINICAL TRIALS
.........................................................................................................
29
DETAILED PHARMACOLOGY
.............................................................................
Přečtěte si celý dokument
